Cellectar Biosciences Showcases Iopofosine Data at ASCO
Florham Park, N.J., April 21, 2026 Cellectar Biosciences, Inc. announced that a subset analysis from its CLOVER WaM clinical...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Florham Park, N.J., April 21, 2026 Cellectar Biosciences, Inc. announced that a subset analysis from its CLOVER WaM clinical...
South San Francisco, California, USA, April 21, 2026 In a significant advancement in precision oncology, IDEAYA Biosciences, Inc. has...
Cambridge, Massachusetts, USA, April 21, 2026 In a major advancement for targeted cancer therapy, Nuvalent, Inc. has announced the...
SAN DIEGO, Calif., April 21, 2026 Cardiff Oncology, Inc. announced it will present updated Phase 2 data for its...
